OutcomesOutcome
Scale for the Assessment of Negative Symptoms (SANS) total score
1 finding from 1 compound ↓reported in points
What moved it
How to read these marks1 finding · 1 compound · 1 null · by evidence strength. No dose is advised.
Scale for the Assessment of Negative Symptoms (SANS) total score
Findings drawn, by strength
1finding · 1 compound
- Very limited1
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
Not pooled · no summary effect · point at a mark · Tab, then the arrow keys
Measured, no difference found1 finding
- GlycineMoved: no difference foundEvidence: Very limitedPaper: PMID 178983522007
- Who
- Inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms, adjunctive glycine against placebo; the D-cycloserine arm is a separate comparison against the same placebo
- Dose studied
- not reported
There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects.”
Quoted verbatim from The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.RCT · 4 monthsPermalink
No row matches these filters.
How it is measured
Total score on the Scale for the Assessment of Negative Symptoms (SANS; Andreasen 1982 and 1984), a clinician-rated scale of 25 items in five domains (affective flattening or blunting, alogia, avolition-apathy, anhedonia-asociality and attention), each rated 0 (none) to 5 (severe); the total is the sum of all items (0 to 125), or the sum of the five global domain ratings (0 to 25), which the source states; higher is worse.
Measured, with no finding
1 measurement
Show what was measuredHide what was measured
Scale for the Assessment of Negative Symptoms (SANS) total score
no effect
Not recorded as a finding: Agentless passive covering four outcomes in one sentence and never naming the compound.
No significant within- or between-group changes were observed for PANSS positive, SANS, CDRS, or MATRICS composite scores (Table 2).
PMID 28289280 · one of two readings recorded this
Papers about it
As an endpoint4
Show the papersHide the papers
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280Via: named in the paper, as read
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
Psychiatry and clinical neurosciences2014PMID 24548129Via: named in the paper, as read
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Neuropsychopharmacology2009PMID 19339966Via: named in the paper, as read
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
The American journal of psychiatry2007PMID 17898352Via: named in the paper, as read
Newest
Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
Molecular psychiatry2018PMID 28289280As an endpoint
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
Psychiatry and clinical neurosciences2014PMID 24548129As an endpoint
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Neuropsychopharmacology2009PMID 19339966As an endpoint
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
The American journal of psychiatry2007PMID 17898352As an endpoint